Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 10

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 10
---
We believe that Mr. Smith is qualified to serve on our board of directors because of his substantial experience in guiding multiple biotech companies through all stages of development as well as deep expertise in finance and corporate governance.

Recommendation of Our Board of Directors

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ELECTION OF THE CLASS I BOARD NOMINEE NAMED ABOVE.

Continuing Directors – Class II Directors

Christian Elling, Ph.D.– Dr. Elling has served on our board of directors since December 2015. Dr. Elling joined Lundbeckfonden, a Danish-based industrial foundation, in March 2012, and has served as Senior Vice President and Managing Partner of its life science company investment unit, Lundbeckfonden BioCapital, since April 2022. He previously served as a Managing Partner of Lundbeckfonden Emerge, the Company’s early stage biotech investment arm, from January 2017 to March 2022. Since 2010, Dr. Elling has served in a number of positions at 7TM Pharma A/S, a biotechnology company, including previously serving as co-founder, Vice President of Biology and Development, and later as Chief Executive Officer. Dr. Elling is a current board member of NMD Pharma A/S, SNIPR Biome and Cytoki Pharma. Dr. Elling received his M.Sc. in Biochemistry and his Ph.D. in Pharmacology from the University of Copenhagen.

We believe that Dr. Elling is qualified to serve on our board of directors because of his expertise and experience in the life sciences industry, his experience as a director of other companies in our industry and his educational background.

Heidi Hunter, M.B.A.– Ms. Hunter has served as a member of our Board of Directors since August 2023. Ms. Hunter most recently served as President of Cardinal Health, where she led the Specialty Solutions Business. Prior to Cardinal Health, Ms. Hunter served as Senior Vice President of the Global Immunology Business Unit at UCB from September 2015 to September 2020. Ms. Hunter also previously held leadership positions at Boehringer Ingelheim as Senior Vice President and General Manager in its Biosimilars Business, and at IQVIA as Vice President of Global Business Partnerships Commercial Solutions. Ms. Hunter held senior leadership positions in commercial and strategic marketing for biologics and oncology at Centocor, a Johnson & Johnson company. She also